# Volitionrx Ltd: overview VNRX · NYSE · CIK 93314 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vnrx.md) · [Financials](/companies/vnrx/financials.md) · [Filings](/companies/vnrx/filings.md) · [Insiders](/companies/vnrx/insiders.md) Latest reported revenue: [$398.7k](/filings/0001477932-26-004995.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001477932-26-004995). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [475](/filings/0001477932-25-008186.md) | [192 d](/filings/0001477932-26-001832.md) | [246](/filings/0001477932-26-003128.md) | [407](/filings/0001477932-26-004995.md) | [627](/filings/0001477932-25-008186.md) | [447 d](/filings/0001477932-26-001832.md) | [985](/filings/0001477932-26-003128.md) | [399](/filings/0001477932-26-004995.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1236.8%)](/filings/0001477932-25-008186.md) | [(3016.5%) d](/filings/0001477932-26-001832.md) | [(2241.1%)](/filings/0001477932-26-003128.md) | [(1548.6%)](/filings/0001477932-26-004995.md) | [(813.2%)](/filings/0001477932-25-008186.md) | [(1077.9%) d](/filings/0001477932-26-001832.md) | [(543.0%)](/filings/0001477932-26-003128.md) | [(1042.5%)](/filings/0001477932-26-004995.md) | | Net margin | % | [(1226.8%)](/filings/0001477932-25-008186.md) | [(3022.8%) d](/filings/0001477932-26-001832.md) | [(2201.3%)](/filings/0001477932-26-003128.md) | [(1545.2%)](/filings/0001477932-26-004995.md) | [(857.4%)](/filings/0001477932-25-008186.md) | [(1402.8%) d](/filings/0001477932-26-001832.md) | [(676.6%)](/filings/0001477932-26-003128.md) | [(1837.7%)](/filings/0001477932-26-004995.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001477932-25-008186.md) | not reported | [(1.12)](/filings/0001477932-26-003128.md) | [(1.22)](/filings/0001477932-26-004995.md) | [(0.05)](/filings/0001477932-25-008186.md) | not reported | [(0.97)](/filings/0001477932-26-003128.md) | [(0.85)](/filings/0001477932-26-004995.md) | | Free cash flow | $k | [(5,524) d](/filings/0001477932-25-008186.md) | [(5,504) d](/filings/0001477932-26-001832.md) | [(4,300)](/filings/0001477932-26-003128.md) | [(6,339) d](/filings/0001477932-26-004995.md) | [(3,631) d](/filings/0001477932-25-008186.md) | [(5,503) d](/filings/0001477932-26-001832.md) | [(5,289)](/filings/0001477932-26-003128.md) | [(5,161) d](/filings/0001477932-26-004995.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001477932-23-001497.md) | [0.3](/filings/0001477932-24-001453.md) | [0.8](/filings/0001477932-25-002231.md) | [1.2](/filings/0001477932-26-001832.md) | [1.7](/filings/0001477932-26-001832.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(31469.0%)](/filings/0001477932-23-001497.md) | [(10372.4%)](/filings/0001477932-24-001453.md) | [(4641.8%)](/filings/0001477932-25-002231.md) | [(2190.9%)](/filings/0001477932-26-001832.md) | [(1258.5%)](/filings/0001477932-26-001832.md) | | Net margin | % | [(29977.0%)](/filings/0001477932-23-001497.md) | [(9986.7%)](/filings/0001477932-24-001453.md) | [(4601.7%)](/filings/0001477932-25-002231.md) | [(2186.3%)](/filings/0001477932-26-001832.md) | [(1352.2%)](/filings/0001477932-26-001832.md) | | Diluted EPS | $ per share | [(0.51)](/filings/0001477932-22-001740.md) | not reported | [(0.50)](/filings/0001477932-25-002231.md) | [(0.31)](/filings/0001477932-25-002231.md) | not reported | | Free cash flow | $m | [(21.8)](/filings/0001477932-23-001497.md) | [(16.8)](/filings/0001477932-24-001453.md) | [(19.1)](/filings/0001477932-25-002231.md) | [(26.2)](/filings/0001477932-26-001832.md) | [(19.8)](/filings/0001477932-26-001832.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vnrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Lagoda Investment Management, L.P.](/funds/1632108.md) | 2026-06-30 | $2.0m | 1,455,950 | | New +1,455,950 | | [LUMINUS MANAGEMENT LLC](/funds/1279151.md) | 2026-06-30 | $211.8k | 156,897 | | New +156,897 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $75.0k | 55,537 | | New +55,537 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $68.4k | 50,684 | | New +50,684 | | [Wealthspire Advisors, LLC](/funds/1646247.md) | 2026-06-30 | $60.8k | 45,000 | | New +45,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $45.9k | 33,995 | | New +33,995 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $34.3k | 25,381 | | New +25,381 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $33.9k | 25,133 | | New +25,133 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $30.1k | 22,308 | | New +22,308 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $17.5k | 12,978 | | New +12,978 | ## Recent filings [All 1,072 filings](/companies/vnrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-25 | 17:00 ET | [8-K](/filings/0001477932-26-005804.md) | 3.02 Unregistered sale of equity | 0001477932-26-005804 | | 2026-09-16 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001493152-26-042962.md) | Ownership report, active investor, amended | 0001493152-26-042962 | | 2026-09-15 | 17:00 ET | [8-K](/filings/0001477932-26-005620.md) | 3.02 Unregistered sale of equity | 0001477932-26-005620 | | 2026-09-14 | 16:45 ET | [8-K](/filings/0001477932-26-005578.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-005578 | | 2026-09-04 | 17:29 ET | [SCHEDULE 13D](/filings/0001493152-26-041611.md) | Ownership report, active investor | 0001493152-26-041611 | | 2026-09-02 | 16:45 ET | [8-K](/filings/0001477932-26-005359.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001477932-26-005359 | | 2026-09-02 | 21:54 ET | [8-K](/filings/0001477932-26-005351.md) | 3.02 Unregistered sale of equity | 0001477932-26-005351 | | 2026-08-24 | 17:00 ET | [8-K](/filings/0001477932-26-005251.md) | 3.02 Unregistered sale of equity | 0001477932-26-005251 | | 2026-08-13 | 16:40 ET | [10-Q](/filings/0001477932-26-004995.md) | Quarterly report, period 2026-06-30 | 0001477932-26-004995 | | 2026-08-13 | 16:32 ET | [8-K](/filings/0001477932-26-004991.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477932-26-004991 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001477932-26-001832.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2b9a6ee0-bdfc-4078-bfc2-8200e5e4b205) ## About the filer - CIK: 93314 - Tickers: VNRX - Exchange: NYSE - SIC code: 2835 In Vitro & In Vivo Diagnostic Substances - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:01 ET. No prices; not investment advice.